However, tumor tissue editing in refractory systems states prompted a novel therapy quality of mTOR inhibitors, here everolimus or temsirolimus, respectively, which could not be achieved with the tissue reprogramming therapy alone (unpublished data). The gene discussed is MTOR; the disease is neoplasm.